DEX Combined With RTX, CSA and IVIG in the Management of Newly Diagnosed ITP Patients
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The project was undertaken by Qilu Hospital, Shandong University in China. In order to report
the efficacy and safety of dexamethasone combined with rituximab, cyclosporin and intravenous
immunoglobulin in the management of newly diagnosed ITP patients.
Phase:
Phase 3
Details
Lead Sponsor:
Shandong University
Collaborators:
Liaocheng People's Hospital Linyi People's Hospital Qingdao University